Preparation method and application of silk fibroin microneedle patch for synergistically resisting inflammation and promoting skin regeneration
By preparing silk fibroin microneedle patches, the timing release of outer dBRD9 and inner SAG was used to solve the problem of poor healing in diabetic wounds, effectively anti-inflammatory and promoting regeneration for diabetic wounds, significantly accelerating the wound healing process .
Patent Information
- Application Number
- CN202411120464.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-22
AI Technical Summary
Chronic complications of poor healing of diabetes wounds cause patients to face the risk of amputation. Existing dressings cannot effectively anti-inflammatory and promote skin regeneration, and there are problems such as drug resistance, first-pass metabolism, and gastrointestinal adverse reactions.
Prepare a silk fibroin microneedle patch that synergizes anti-inflammatory and promotes skin regeneration. It quickly inhibits the macrophage response during the inflammatory phase through the outer loading drug dBRD9, and the inner loading drug SAG delays activation of the hedgehog signaling pathway, and uses microneedle to penetrate the skin. The dual advantages of drug administration and silk fibroprotein materials achieve the timing release of drugs.
Effectively inhibit the inflammatory response of diabetic wounds, accelerate re-epithelialization, promote diabetic wound healing, improve the mechanical strength and bioavailability of wound healing, and reduce systemic side effects.
Smart Images

Figure CN118986939A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomaterials, and in particular to a preparation method and application of a silk fibroin microneedle patch capable of synergistically resisting inflammation and promoting skin regeneration. Background Art
[0002] Diabetes is a major global health problem, affecting nearly 500 million people each year and causing more than 1 million deaths. Poor wound healing is a common chronic complication of diabetes. About 15% to 25% of diabetic patients suffer from difficult-to-heal wounds such as diabetic foot ulcers, and 80% of them face the risk of amputation. However, despite the huge market demand, the clinical treatment of diabetic wounds still faces many challenges.
[0003] The skin wound healing process goes through three consecutive and overlapping stages: inflammation, proliferation, and reconstruction. The wounds of diabetic patients are often in a state of persistent chronic inflammation, with microcirculation disorders and dysfunction of key cells such as fibroblasts and keratinocytes. These pathological factors lead to the lack of corresponding biological functions of traditional wound dressings, which cannot effectively protect wounds and are prone to complications such as secondary infection and vascular damage. Although oral antibiotics and anti-inflammatory drugs can control infection and inflammation to a certain extent, they have many problems such as drug resistance, first-pass metabolism, and gastrointestinal adverse reactions. Summary of the invention
[0004] The purpose of the present invention is to develop a novel bioactive dressing to improve the microenvironment of diabetic wounds and solve many difficulties faced in the clinical treatment of diabetic wounds.
[0005] In order to achieve the above object, the present invention provides a method for preparing a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion, which comprises at least the following steps:
[0006] Step 1, boiling silkworm cocoons to remove sericin to obtain silk fibroin, mixing the silk fibroin with a lithium bromide solution, incubating the mixture in a water bath at 60° C. to dissolve the silk fibroin, and dialyzing the mixture in an aqueous solution to obtain a silk fibroin solution;
[0007] Step 2, placing the silk fibroin solution in a 60° C. oven for rapid concentration for 24 hours, and then gradually concentrating it in a fume hood for 3 days, so that the silk fibroin concentration in the silk fibroin solution reaches at least 25 wt %, to obtain a concentrated silk fibroin solution;
[0008] Step 3, diluting the concentrated silk fibroin solution, sealing and placing at 60° C. for incubation to obtain a silk fibroin nanofiber solution;
[0009] Step 4, adding glycerol to the silk fibroin solution, adding drug dBRD9 after thorough mixing to obtain an outer layer solution, transferring the outer layer solution to a microneedle mold, and removing excess liquid from the upper layer by centrifugation;
[0010] Step 5, adding drug SAG to the silk fibroin nanofiber solution, mixing the silk fibroin nanofiber solution after adding drug SAG with the silk fibroin solution to obtain an inner layer solution, transferring the inner layer solution to the microneedle mold, and centrifuging to remove excess liquid in the upper layer;
[0011] Step 6, adding 20% polyvinyl alcohol into the microneedle mold and letting it stand to obtain a silk fibroin microneedle patch.
[0012] Preferably, in step 1, after dissolving the silk fibroin, the process further comprises: dialyzing the dissolved silk fibroin solution in deionized water for 2 days, centrifuging the dialyzed protein solution at 9000 rpm at 4°C for 20 minutes, and obtaining the supernatant after centrifugation as the silk fibroin solution to be used.
[0013] Preferably, in step 3, the concentrated silk fibroin solution is diluted to 2 wt % with ultrapure water, mixed evenly, and then sealed and incubated at 60° C. to obtain a silk fibroin nanofiber solution.
[0014] Preferably, in step 4, the mass ratio of the silk fibroin to glycerol is 1:(0.2-0.6).
[0015] Preferably, in step 4, the concentration of the drug dBRD9 in the outer layer solution is 100 μM.
[0016] Preferably, in step 5, the concentration of the drug SAG in the inner layer solution is 200 μM.
[0017] Preferably, in step 5, the volume ratio of the silk fibroin nanofiber solution after adding the drug SAG: the silk fibroin solution is 1:1.
[0018] The present invention also provides an application of a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion, wherein the silk fibroin microneedle patch is used for preparing a medicine for treating diabetic wound healing.
[0019] Preferably, the silk fibroin microneedle patch rapidly releases the loaded outer layer drug dBRD9 in the early stage of wound healing to inhibit the inflammatory response of macrophages in the inflammatory stage, and delays the release of the loaded inner layer drug SAG to activate the hedgehog signaling pathway in the late stage of wound healing to promote re-epithelialization in the proliferation and reconstruction stage, synergistically fight inflammation and promote skin regeneration, thereby promoting diabetic wound healing.
[0020] Preferably, the drug release rate of the outer layer drug dBRD9 loaded on the silk fibroin microneedle patch is greater than the drug release rate of the inner layer drug SAG loaded on the silk fibroin microneedle patch.
[0021] Compared with the prior art, the beneficial effects of the present invention include at least:
[0022] The present invention prepares a silk fibroin microneedle patch, wherein the outer layer of the silk fibroin microneedle patch is loaded with silk fibroin containing drug dBRD9, which is induced by polyol to form β-sheets and has sufficient mechanical strength, and the loaded drug dBRD9 is rapidly released in the early stage of wound healing to inhibit the inflammatory response of macrophages in the inflammatory stage; the inner layer of the silk fibroin microneedle patch is loaded with silk fibroin nanofiber containing drug SAG, which realizes the delayed release of SAG through electrostatic adsorption and physical barrier effect to activate the hedgehog signaling pathway in the late stage of wound healing and promote re-epithelialization in the proliferation and reconstruction stage; the silk fibroin microneedle patch of the present invention utilizes the dual advantages of microneedle transdermal drug delivery and silk fibroin materials, and uses the inner and outer double-layer silk fibroin microneedle patch as a drug delivery system for diabetic wounds, which can match the physiological process of wound healing, target the key pathological factors that make diabetic wounds difficult to heal, synergistically fight inflammation and promote skin regeneration, and effectively accelerate the healing of diabetic wounds. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is a diagram of the experimental results of the present invention to explore the mechanism of difficulty in diabetic wound healing.
[0024] Figure 2 This figure shows the experimental results that hedgehog signaling activation cannot promote skin fibroblast proliferation and angiogenesis under inflammatory conditions.
[0025] Figure 3 The present invention is a flow chart for preparing a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion.
[0026] Figure 4 This is a morphological observation diagram of a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion prepared by the present invention.
[0027] Figure 5 This is an atomic force microscopy result diagram of detecting the interaction between silk fibroin nanofibers and SAG according to the present invention.
[0028] Figure 6 This is a comparison chart of the drug release rates of the inner and outer layers of a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion prepared by the present invention.
[0029] Figure 7This is a diagram showing the therapeutic effect of a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion prepared by the present invention applied to skin wounds of type II diabetic mice.
[0030] Figure 8 This is a graph showing the experimental results of a study on the mechanism of the silk protein microneedle patch prepared by the present invention that synergistically fights inflammation and promotes skin regeneration in promoting skin wound healing in type II diabetic mice. DETAILED DESCRIPTION
[0031] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0032] The experimental materials not mentioned in this invention are all conventional experimental materials, and the experimental methods not mentioned are all conventional experimental methods.
[0033] Diabetes is a major global health problem, affecting nearly 500 million people each year and causing more than 1 million deaths. Poor wound healing is a common chronic complication of diabetes. About 15% to 25% of diabetic patients suffer from difficult-to-heal wounds such as diabetic foot ulcers, and 80% of them face the risk of amputation. However, despite the huge market demand, the clinical treatment of diabetic wounds still faces many challenges.
[0034] The skin wound healing process goes through three continuous and overlapping stages: inflammation, proliferation and reconstruction. Excessive inflammatory response of the wound and dysregulation of key signaling pathways such as hedgehog cause dysfunction of fibroblasts and keratinocytes, which are important reasons for the difficulty in healing diabetic wounds. Therefore, the present invention hopes to match the physiological process of wound healing, target the key pathological factors of the difficulty in healing diabetic wounds, achieve anti-inflammatory in the inflammation phase of wound healing, accelerate re-epithelialization in the proliferation and reconstruction phase, and effectively promote diabetic wound healing.
[0035] In recent years, drug-loaded microneedle patches have gradually become a new type of wound dressing that has attracted much attention. Microchannels are created by microneedles, which significantly enhance the skin penetration rate of drugs, directly deliver drugs to the skin, improve the bioavailability of drugs, reduce systemic side effects, and are easy to operate, painless, and have high patient compliance. Silk protein is a natural biomaterial with excellent biocompatibility, plasticity and degradability. The present invention utilizes the dual advantages of microneedle transdermal drug delivery and silk protein materials to design a double-layer drug-loaded silk protein microneedle patch, the outer layer is loaded with PROTAC dBRD9 (R&D Systems, 6606, CAS NO.: 2341840-98-8) (dBRD9) to inhibit the inflammatory response of macrophages in the wound inflammation period, and the inner layer is loaded with smoothened agonist (SAG) activator (Selleck, S7779, CAS NO.: 2095432-58-7) to promote re-epithelialization in the wound proliferation and reconstruction period, and realize the timed release of the two drugs, effectively accelerating the healing of diabetic wounds.
[0036] 1. Research on the mechanism of difficulty in diabetic wound healing
[0037] To study the mechanism of wound healing difficulties in diabetic mice, Figure 1 As shown, 9 days after surgery, iNOS ( Figure 1 a red), STAT1( Figure 1 b red), GLI1( Figure 1 c red), CCND1( Figure 1 d red), PTCH-1 ( Figure 1 e (red) Immunofluorescence staining indicated that compared with control mice, the inflammatory response in skin wounds of db / db type II diabetic mice was overactivated and the hedgehog signaling pathway was inhibited, resulting in difficulty in wound healing.
[0038] 2. Under inflammatory conditions, Hedgehog signaling activation cannot promote skin fibroblast proliferation and angiogenesis
[0039] RAW 264.7 cells were plated at 3*10 6 The cells were inoculated in 6-well plates at a density of 100 ng / ml and cultured in complete medium containing 100 ng / ml LPS or an equal amount of water for 48 h before the culture medium was collected. The collected culture medium was centrifuged at 1000 rpm for 3 min. After filtering using a 0.2 μm filter, the supernatant (RAW264.7 supernatant after LPS stimulation was recorded as sti-RAW 264.7suspension, and RAW264.7 supernatant without LPS stimulation was recorded as RAW 264.7suspension) was collected and co-cultured with skin fibroblasts or vascular endothelial cells, and supplemented with 1 μM SAG or an equal amount of water for functional assay evaluation. Figure 2 a is the detection result of dermal fibroblast cck-8 (Dojindo Kagaku, Japan) after 24h, 48h and 72h of co-culture, n=5 biological independent samples. Figure 2 b shows the Ki67 (red) and EdU (green) fluorescence staining of dermal fibroblasts after 48 h of co-culture, and the yellow arrows indicate proliferating cells. Figure 2 c is an in vitro scratch test of dermal fibroblasts after 48 h of co-culture.
[0040] Experimental results: Figure 2 a, b, and c indicate that under inflammatory conditions, activation of Hedgehog signaling through SAG cannot promote the proliferation and migration ability of dermal fibroblasts. Figure 2 d is a representative image of HUVEC tube formation after 2 h of co-culture. Figure 2 The e is Figure 2 Quantitative results of d, n = 5 biologically independent samples. Figure 2 d and e indicate that under inflammatory conditions, activation of Hedgehog signaling through SAG cannot promote the angiogenesis ability of HUVECs. Figure 2 Scale bar is 200 μm. All experiments were performed in triplicate unless otherwise stated.
[0041] 3. Preparation of a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration
[0042] like Figure 3 As shown, the preparation method of a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion of the present invention comprises the following steps:
[0043] Step 1, boil 5g of chopped silkworm cocoons in 2L 0.02M Na2CO3 solution for 30 minutes to remove sericin, rinse three times with distilled water to obtain silk fibroin (RSF). The rinsed silk fibroin is mixed in a ratio of 1g silk fibroin to 4ml 9.3M lithium bromide solution, and incubated in a 60°C water bath for 4 hours until the silk fibroin is completely dissolved. The dissolved silk fibroin solution is dialyzed in deionized water for 2 days. The dialyzed protein solution is centrifuged at 4°C, 9000rpm for 20 minutes, and the supernatant is the silk fibroin solution, which is stored in a 4°C refrigerator for standby use.
[0044] Step 2: The silk fibroin solution was rapidly concentrated in an oven at 60° C. for 24 hours, and gradually concentrated in a fume hood for 3 days to make the silk fibroin concentration in the silk fibroin solution reach about 25 wt %. Then, the silk fibroin solution was stabilized in a refrigerator at 4° C. for 2 days.
[0045] Step 3, dilute the concentrated silk fibroin solution with ultrapure water to 2 wt%, and mix thoroughly with a magnetic stirrer, and then seal and incubate at 60° C. to finally form a silk fibroin nanofiber solution.
[0046] Step 4, glycerol was added to the silk fibroin solution to achieve a ratio of 1:0.4 between the silk fibroin solution and glycerol, and the drug dBRD9 was added after thorough mixing, with the final concentration of the drug dBRD9 being 100 μM. Then 50 μL of the solution was transferred to the microneedle mold, centrifuged at 4500 rpm for 5 minutes to remove bubbles, and the supernatant was aspirated and incubated at 37°C for 4 hours.
[0047] Step 5, the silk fibroin nanofiber solution is ultrasonically treated, filtered and sterilized, and the drug SAG is added, the final concentration of the drug SAG is 200 μM, the silk fibroin nanofiber solution after the addition of the drug SAG is mixed with the silk fibroin solution in a 1:1 ratio, centrifuged again at 4500 rpm for 5 minutes, and incubated at 37°C for 30 minutes after removing the supernatant.
[0048] Step 6, adding 20% polyvinyl alcohol into the microneedle mold and letting it stand to obtain a silk fibroin microneedle patch.
[0049] 4. Morphological observation of silk fibroin microneedle patch
[0050] like Figure 4 As shown, the morphology of the silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion prepared by the present invention was observed. Figure 4 An optical microscope, Figure 4 The scanning electron microscope of b shows that the microneedles in the microneedle patch are 650 μm high and 350 μm in diameter. Figure 4 The confocal microscope can be used to observe that the microneedle patch has an obvious double-layer structure. Figure 4 The scale bar of a is 1 mm, Figure 4 Scale bar in b is 100 μm, Figure 4 Scale bar in c is 200 μm.
[0051] 5. Atomic force microscopy to detect the interaction between silk fibroin nanofibers and SAG
[0052] After ultrasonic treatment, silk fibroin nanofibers (NSF) Figure 5 The a shows that the silk fibroin nanofibers have short fibers. Figure 5 (b) shows that the size and width of silk fibroin nanofibers increased significantly after mixing with SAG, which indicates that SAG may bind to silk fibroin nanofibers through electrostatic interactions.
[0053] VI. Evaluation of drug release rate of inner and outer layers of silk fibroin microneedle patch
[0054] The drug release rate of the inner and outer layers of the silk fibroin microneedle patch prepared by the present invention was evaluated. Figure 6 As shown in the figure, the outer layer model drug RB 6G is released quickly, releasing about 40% in the first 4 hours, while the inner layer model drug FAM releases about 15%, and there is a significant difference in the release rate between the two. By 72 hours, the drug release rate of the inner and outer layers reaches about 80%. The model drug molecule is easy to detect, and the mechanism of the model drug molecule is the same as that of the inner and outer layer drugs, so it can basically represent the actual release of the inner and outer layer drugs.
[0055] VII. Application of Silk Fibroin Microneedle Patch in the Treatment of Skin Wounds in Type II Diabetic Mice
[0056] Skin wound healing of HFD / STZ-induced type II diabetic mice 8 days after surgery using double-layer unloaded silk fibroin microneedle patch, single-layer loaded dBRD9 silk fibroin microneedle patch, single-layer loaded SAG silk fibroin microneedle patch, and double-layer drug-loaded dBRD9 / SAG silk fibroin microneedle patch ( Figure 7 A) Comparison of wound size ( Figure 7 B), H&E staining ( Figure 7 C), Masson trichrome staining ( Figure 7 D). The experiment showed that compared with the unloaded and single-layer drug-loaded silk fibroin microneedle patches, the double-layer drug-loaded silk fibroin microneedle patches significantly promoted wound re-epithelialization and accelerated wound healing in type II diabetic mice. Figure 7 The box in the left image of C and D is shown at a higher magnification on the right. The black dashed line is the wound boundary, the white dashed line outlines the dermis, the yellow arrow indicates the collagen bundle, and the asterisk indicates the infiltrating inflammatory cell. The scale bar is 200 μm. Three biologically independent samples were set up for all experiments in this figure.
[0057] 8. Study on the mechanism of silk fibroin microneedle patch promoting skin wound healing in type II diabetic mice
[0058] The double-layer drug-loaded silk fibroin microneedle patch prepared by the present invention was used to treat the skin wounds of db / db type II diabetic mice. The iNOS( Figure 8 a red), STAT1( Figure 8 b red), TNF-α( Figure 8 c red) immunofluorescence staining, the experimental results show that compared with the double-layer silk fibroin microneedle patch without drug loading, the double-layer silk fibroin microneedle patch significantly inhibited the inflammatory response of the wound healing inflammatory phase in type II diabetic mice. GLI1 ( Figure 8 d red), CCND1( Figure 8 e red), PTCH-1 ( Figure 8 f (red) immunofluorescence staining, indicating that compared with the double-layer silk fibroin microneedle patch without drug loading, the double-layer silk fibroin microneedle patch reactivated the hedgehog signaling pathway during the proliferation and reconstruction phase of wound healing in type II diabetic mice. The box on the left side of the figure is shown at a higher magnification on the right side, the white dotted line outlines the boundary of the wound, the yellow arrow indicates the positive signal, the scale bar is 200μm, and all experiments were set up with 3 biologically independent samples.
[0059] In summary, the present invention prepares a synergistic anti-inflammatory and skin regeneration-promoting silk protein microneedle patch and a preparation method thereof, utilizing the dual advantages of microneedle transdermal drug delivery and silk protein materials, using an inner and outer double-layer silk protein microneedle patch as a drug delivery system for diabetic wounds, the outer layer of the silk protein microneedle patch is a silk protein loaded with drug dBRD9, which is induced by polyols to form a β-sheet, and has sufficient mechanical strength, and the loaded drug dBRD9 is rapidly released in the early stage of wound healing to inhibit the inflammatory response of macrophages in the inflammatory phase; the inner layer of the silk protein microneedle patch is a silk protein nanofiber loaded with drug SAG, and the delayed release of SAG is achieved through electrostatic adsorption and physical barrier effects to activate the hedgehog signaling pathway in the late stage of wound healing and promote re-epithelialization in the proliferation and reconstruction phase. The silk protein microneedle patch of the present invention can match the physiological process of wound healing, target the key pathological factors of diabetic wounds that are difficult to heal, synergistically fight inflammation and promote skin regeneration, and effectively accelerate the healing of diabetic wounds.
[0060] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.
Claims
1. A method for preparing a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion, characterized in that: At least the following steps are included: Step 1, boiling silkworm cocoons to remove sericin to obtain silk fibroin, mixing the silk fibroin with a lithium bromide solution, incubating the mixture in a water bath at 60° C. to dissolve the silk fibroin, and dialyzing the mixture in an aqueous solution to obtain a silk fibroin solution; Step 2, placing the silk fibroin solution in a 60° C. oven for rapid concentration for 24 hours, and then gradually concentrating it in a fume hood for 3 days, so that the silk fibroin concentration in the silk fibroin solution reaches at least 25 wt %, to obtain a concentrated silk fibroin solution; Step 3, diluting the concentrated silk fibroin solution, sealing and placing at 60° C. for incubation to obtain a silk fibroin nanofiber solution; Step 4, adding glycerol to the silk fibroin solution, adding drug dBRD9 after thorough mixing to obtain an outer layer solution, transferring the outer layer solution to a microneedle mold, and removing excess liquid from the upper layer by centrifugation; Step 5, adding drug SAG to the silk fibroin nanofiber solution, mixing the silk fibroin nanofiber solution after adding drug SAG with the silk fibroin solution to obtain an inner layer solution, transferring the inner layer solution to the microneedle mold, and centrifuging to remove excess liquid in the upper layer; Step 6, adding 20% polyvinyl alcohol into the microneedle mold and letting it stand to obtain a silk fibroin microneedle patch.
2. The preparation method according to claim 1, characterized in that In step 1, after the silk fibroin is dissolved, the method further comprises: dialyzing the dissolved silk fibroin solution in deionized water for 2 days, centrifuging the dialyzed protein solution at 9000 rpm at 4° C. for 20 minutes, and obtaining the supernatant after centrifugation as the silk fibroin solution to be used.
3. The preparation method according to claim 1, characterized in that: In step 3, the concentrated silk fibroin solution is diluted to 2 wt % with ultrapure water, mixed evenly, and then sealed and incubated at 60° C. to obtain a silk fibroin nanofiber solution.
4. The preparation method according to claim 1, characterized in that: In step 4, the mass ratio of the silk fibroin to glycerol is 1: (0.2-0.6).
5. The preparation method according to claim 1, characterized in that: In step 4, the concentration of the drug dBRD9 in the outer layer solution is 100 μM.
6. The preparation method according to claim 1, characterized in that: In step 5, the concentration of the drug SAG in the inner layer solution is 200 μM.
7. The preparation method according to claim 1, characterized in that: In step 5, the volume ratio of the silk fibroin nanofiber solution after adding the drug SAG to the silk fibroin solution is 1:
1.
8. An application of a silk fibroin microneedle patch for synergistic anti-inflammatory and skin regeneration promotion, characterized in that: The silk fibroin microneedle patch is used for preparing a medicine for treating diabetic wound healing.
9. The use according to claim 8, characterized in that The silk fibroin microneedle patch rapidly releases the loaded outer layer drug dBRD9 in the early stage of wound healing to inhibit the inflammatory response of macrophages in the inflammatory stage, and delays the release of the loaded inner layer drug SAG to activate the hedgehog signaling pathway in the late stage of wound healing to promote re-epithelialization in the proliferation and reconstruction stage, synergistically fight inflammation and promote skin regeneration, thereby promoting diabetic wound healing.
10. The use according to claim 9, characterized in that The drug release rate of the outer layer drug dBRD9 loaded on the silk fibroin microneedle patch is greater than the drug release rate of the inner layer drug SAG loaded on the silk fibroin microneedle patch.
